We don't advocate for a separate formulary and process for the diabetes medications, nor for other drugs. We agree with you that if the common drug review was working, if it was open and transparent, and if there was some ability for Canadians to identify that the right people were being consulted, and if we understood what the economic analysis was, we would be supportive of it. That was the promise that this common drug review gave back when it was created.
We also know that the provinces and territories and the federal government, all the participating drug plans, also said that once the common drug review was up and running, they would stop doing their own reviews and just do the budgetary cost impact. Well, they haven't. Ontario, in fact, has introduced changes to their drug system that enhance the role of the committee to evaluate drugs. They review the same materials and information, and do their own cost analysis, actually, on those drugs, to reach the same conclusion as the common drug review does. Sometimes it's a different conclusion, actually.
So the duplication in the system hasn't been removed; in fact, it has been increased. That's the delay in access, right?